Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels
| Status: | Archived |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
| End Date: | February 2011 |
Exploratory Study of Xolair (Omalizumab)to Improve Outcomes in Patients With COPD and Elevated IgE Levels, and Positive RAST or Skin Prick Tests
The objective is to conduct an exploratory study on the effect of Omalizumab on COPD
patients with elevated IgE. Exploratory outcomes include to determine whether Omalizumab
use: reduces exacerbations in COPD patients; or improves rescue medication use, decreases
ICS use, modified Medical Research Council (MMRC) dyspnea score, St. George's Respiratory
Questionnaire (SGRQ), 6-minute walk distance (6MWD), forced expiratory volume at one second
(FEV1)(the latter 3 with BMI make up the BODE score), residual volume (RV), total lung
capacity (TLC), exhaled nitric oxide (ENO), and determination C-reactive protein (CRP).
We found this trial at
1
site
National Jewish Health National Jewish Health is known worldwide for treatment of patients with respiratory,...
Click here to add this to my saved trials
